Item 7.01. Regulation FD Disclosure.
Arcturus Therapeutics Holdings Inc. (the "Company") plans to discuss the
information contained in the presentation attached to this Current Report on
Form 8-K as Exhibit 99.1 with third parties in San Francisco, California.
The furnishing of the attached presentation is not an admission as to the
materiality of any information therein. The information contained in the slides
is summary information that is intended to be considered in the context of more
complete information included in the Company's filings with the SEC and other
public announcements that the Company has made and may make from time to time by
press release or otherwise. The Company undertakes no duty or obligation to
update or revise the information contained in this report, although it may do so
from time to time as its management believes is appropriate. Any such updating
may be made through the filing of other reports or documents with the SEC,
through press releases or through other public disclosures. For important
information about forward looking statements, see the slide titled
"Forward-looking Statements" in Exhibit 99.1 attached hereto.
The information in this Item 7.01 of this Current Report on Form 8-K and Exhibit
99.1 attached hereto shall not be deemed "filed" for purposes of Section 18 of
the Exchange Act, or otherwise subject to the liabilities of that section or
Sections 11 and 12(a)(2) of the Securities Act. The information contained in
this Item 7.01 and in the presentation attached as Exhibit 99.1 to this Current
Report shall not be incorporated by reference into any filing with the SEC made
by the Company, whether made before or after the date hereof, regardless of any
general incorporation language in such filing.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits.
Exhibit No. Description of Exhibit
99.1 Presentation dated January 2020
© Edgar Online, source Glimpses